Diabetes

BioAsia 2020

Digital strategies key for Indian pharma

February 21, 2020

HYDERABAD, India – To continue expanding their footprint and capabilities beyond simple generics to biosimilars and new chemical entities, Indian pharmaceutical companies will have to improve their quality controls, compliance capabilities and, just as importantly, adopt more effective digital strategies.

Vtv scores phase II TD in T1D as Alzheimer’s bid RAGEs against dying of light

February 10, 2020

By Randy Osborne

No Comments

With the Simpliciti-T1 phase II trial testing new-mechanism TTP-399 as adjunct therapy in type 1 diabetes (T1D), High Point, N.C.-based Vtv Therapeutics Inc. nailed the HbA1c endpoint with none of the safety concerns foiling developers of type 2 diabetes (T2D) drugs who sought to broaden their labels.

Oculis’ topical DME drug hits phase II endpoints, validates nanoparticle delivery solution

February 10, 2020

By Nuala Moran

No Comments

LONDON – Oculis SA reported positive results for its topical nanoparticle formulation of dexamethasone in the treatment of diabetic macular edema (DME), showing the eye drops reduced central macular thickness (CMT) in the phase II proof-of-concept trial.

Precision Medicine World Conference

Verily highlights diabetes care, Project Baseline even as related partnerships are restructured

January 24, 2020

By Stacy Lawrence

No Comments

SANTA CLARA, Calif. – Diabetes seems likely to be the first area to really show concrete products and results for the ambitious Verily Life Sciences, which is the med-tech business of Mountain View, Calif.-based Google parent Alphabet Inc. However, its two major diabetes partners both have been rethinking the relationship.

Unintended consequences of BPCIA dog insulin prices

July 17, 2019

By Mari Serebrov

No Comments

Perhaps the hardest hit by the unintended consequences of well-intentioned legislation, U.S. insulin products continue to be the congressional poster child of all that's wrong with drug prices in America.

Hanmi shares slip as Janssen opts to return rights to diabetes and obesity drug HM-12525A

July 9, 2019

By Jihyun Kim

No Comments

HONG KONG – Belgian drugmaker Janssen Pharmaceutical NV, a subsidiary of Johnson & Johnson, has decided to return the rights of diabetic obesity treatment HM-12525A to Hanmi Pharmaceuticals Co. Ltd. The South Korean company said the decision followed phase II testing by Janssen, which showed the drug achieved the weight loss endpoint but didn't reach Janssen's internal criteria for blood glucose control in obese patients with diabetes.

Sernova takes aim at type 1 diabetes with Cell Pouch for islet implant

July 5, 2019

By Mark McCarty

No Comments

The artificial pancreas represents a dramatic improvement over existing approaches to management of diabetes, but Sernova Corp. of London, Ontario, is intent on going one better on conventional device technology. The company recently presented the results from an early phase study of its Cell Pouch device with pancreatic islet cells to a major medical conference, and the results suggest that the Cell Pouch with islets will pass the safety bar and may prove efficacious for several measures, including glycemic control.

It’s the Pounds, Stupid

May 24, 2012

By Marie Powers

No Comments

At a family wedding earlier this month, an uncle was salivating over the prospect that the Vivus Inc. drug Qnexa could soon become the first in a new generation of obesity drugs to gain FDA approval. He needed to lose 50 pounds, he confided, and the drug seemed the answer to his prayers. Since we’ve written extensively about obesity and these drugs in BioWorld Today, he wanted my opinion. I politely inquired whether he had considered dieting and exercise, which could produce similar results without the potential side effects of a prescribed drug – especially one in a category that’s...